My Dose Coach Inquiry

Skip To Main Content

This website is intended exclusively for healthcare professionals residing and/or working in the KSA.

Campus

Login
Registration

Science
Acquired Thrombotic Thrombocytopenic Purpura (ATTP)
Anti-Infectives
Asthma
Atopic Dermatitis
Chronic Obstructive Pulmonary Disease
Diabetes
Eosinophilic Esophagitis
Multiple Myeloma
Multiple Sclerosis
Neurological Disorders
Prurigo Nodularis
Rare Diseases
Transplant
Nasal Polyps

Cardiovascular
Atherothrombosis
Dyslipidemia
Hypertension
Thrombosis

Vaccines
Influenza
RSV

Patient Support
Allergic Rhinitis
Atopic Dermatitis
Cardiovascular
Rare Diseases

Diabetes
MyDose Coach

Product
Apidra®
Aprovasc®
Beyfortus®
Cerezyme®
Myozyme®
Nexviazyme
Renvela®
Solian®
Xatral®
Xenpozyme®

Aldurazyme®
Dosing Calculator
Expert's Videos

Aubagio®
Aubagio vs Ofatumumab

Cablivi®
aTTP Sphere Digital Case Library

Clexane®
Surgical Patients
Hemodialysis

Dupixent®
Atopic Dermatitis
Prurigo Nodularis

Fabrazyme®
Quantifying the Effect of Fabrazyme
Canadian Fabry Disease Initiative
Long Term Renal Function
FASTEX FAbry Stabilization Index

Plavix®
Tolerability

Praluent®

Praluent®
LDL-C Control
Tolerability
Patients at CV Risk
Starting Praluent®

It's Praluent of Course
Of Course
What is PRALUENT®?
Why choose PRALUENT®?
How to use PRALUENT®?

Rezurock®
Safety
Mechanism of Action
Dosing

Impact of cVGHD
Challenges of Disease Progression

Efficacy
Efficacy Data

Sarclisa®
Sarclisa®
Sarclisa KD®
Sarclisa PD®

Soliqua®
For a Peaceful Ramadan
Soli-Simplify Study
Soliqua®
Soliqua Safety®
Soliqua Simplicity®
Soliqua Guidelines®
Soliqua Data Set®
Soliqua Easy Start®
Soliqua SoliD®

Solosmart
Discover SoloSmart®
HCP Start
Clinical Evidence
Support Your Patients
Patients Faqs

Toujeo®
Toujeo for a Peaceful Ramadan
Wall of Evidence
How to Start
Time in Range

Toujeo T1DM
OneCare
Edition Junior
UltraFlexi-1
Type-1 Meta Analysis
Guidelines

Toujeo T2DM
Deliver-G
Guidelines

Toujeo Innovation
Toujeo Upgrade to Win

Zympass®
Tolerability
Usage

Campus

Science
Acquired Thrombotic Thrombocytopenic Purpura (ATTP)
Anti-Infectives
Asthma
Atopic Dermatitis
Chronic Obstructive Pulmonary Disease
Diabetes
Eosinophilic Esophagitis
Multiple Myeloma
Multiple Sclerosis
Neurological Disorders
Prurigo Nodularis
Rare Diseases
Transplant
Nasal Polyps

Cardiovascular
Atherothrombosis
Dyslipidemia
Hypertension
Thrombosis

Vaccines
Influenza
RSV

Patient Support
Allergic Rhinitis
Atopic Dermatitis
Cardiovascular
Rare Diseases

Diabetes
MyDose Coach

Product
Apidra®
Aprovasc®
Beyfortus®
Cerezyme®
Myozyme®
Nexviazyme
Renvela®
Solian®
Xatral®
Xenpozyme®

Aldurazyme®
Dosing Calculator
Expert's Videos

Aubagio®
Aubagio vs Ofatumumab

Cablivi®
aTTP Sphere Digital Case Library

Clexane®
Surgical Patients
Hemodialysis

Dupixent®
Atopic Dermatitis
Prurigo Nodularis

Fabrazyme®
Quantifying the Effect of Fabrazyme
Canadian Fabry Disease Initiative
Long Term Renal Function
FASTEX FAbry Stabilization Index

Plavix®
Tolerability

Praluent®

Praluent®
LDL-C Control
Tolerability
Patients at CV Risk
Starting Praluent®

It's Praluent of Course
Of Course
What is PRALUENT®?
Why choose PRALUENT®?
How to use PRALUENT®?

Rezurock®
Safety
Mechanism of Action
Dosing

Impact of cVGHD
Challenges of Disease Progression

Efficacy
Efficacy Data

Sarclisa®
Sarclisa®
Sarclisa KD®
Sarclisa PD®

Soliqua®
For a Peaceful Ramadan
Soli-Simplify Study
Soliqua®
Soliqua Safety®
Soliqua Simplicity®
Soliqua Guidelines®
Soliqua Data Set®
Soliqua Easy Start®
Soliqua SoliD®

SoloSmart®
Discover SoloSmart®
HCP Start
Clinical Evidence
Support Your Patients
Patients Faqs

Toujeo®
Toujeo for a Peaceful Ramadan
Wall of Evidence
How to Start
Time in Range

Toujeo T1DM
OneCare
Edition Junior
UltraFlexi-1
Type-1 Meta Analysis
Guidelines

Toujeo T2DM
Deliver-G
Guidelines

Toujeo Innovation
Toujeo Upgrade to Win

Zympass®
Tolerability
Usage

Login
Registration

Fill out online form.

Campus

Back to top

Legal notice Cookie policy Privacy policy Sitemap Change country

© Sanofi 2004- - All rights reserved

MAT-SA-2100978/V8/APR2024

SANOFI, Kingdom of Saudi Arabia, P.O. Box 9874, Jeddah 21423, K.S.A. Tel: +966-12-669-3318,

Fax: +966-12-663-6191

For further medical information, please contact: +966-12-669-3318 or send an email to:
ksa.medicalinformation@sanofi.com

In case of any drug related adverse events, please contact The National Pharmacovigilance Center (NPC):
Call Center: 19999, E-mail: npc.drug@sfda.gov.sa, Website: https://ade.sfda.gov.sa/
and Sanofi Pharmacovigilance department: Phone: +966-544-284-797, E-mail:
Ksa_pharmacovigilance@sanofi.com

To report any product technical complaints, kindly contact: Email: quality.greatergulf@sanofi.com

leave-site-modal-text

You Will Now Be Leaving the Site

By clicking on this link, you will be leaving Campus Sanofi website and going to another, entirely independent website.
Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but their own.